Does Blue Cross Blue Shield of Michigan Cover Lantus?

How BCBSM Formulary Placement Works for Lantus

Blue Cross Blue Shield of Michigan organizes prescription drugs into tiers that determine your out-of-pocket responsibility. Lantus has historically appeared on Tier 3 (non-preferred brand) across most BCBSM commercial plans, while biosimilar insulin glargine products occupy Tier 2 (preferred brand).

This tiering reflects a broader industry pattern. The American Diabetes Association's 2024 Standards of Care notes that basal insulin analogs, including glargine, remain first-line injectable therapy for patients who need basal coverage beyond what oral agents provide [1]. BCBSM aligns with this by covering glargine products without blanket prior authorization for most Type 1 diabetes members.

Your specific plan document (the Summary of Benefits and Coverage, or SBC) determines exact cost-sharing. Group employer plans negotiated through BCBSM may place Lantus on a different tier than individual marketplace plans purchased through Healthcare.gov. The Blue Care Network HMO formulary and the BCBSM PPO formulary are separate documents with different tier assignments.

To verify your current tier, log into the BCBSM member portal or call the number on your insurance card. Formularies update annually (sometimes mid-year), so a tier placement confirmed in January may shift by July.

Lantus vs. Biosimilar Insulin Glargine: Cost Implications on BCBSM Plans

The FDA has approved several biosimilar and interchangeable insulin glargine products that BCBSM often places on a lower cost tier than brand-name Lantus. Semglee (insulin glargine-yfgn) received interchangeable designation from the FDA in July 2021, meaning pharmacists in Michigan can substitute it for Lantus without prescriber intervention [2].

Rezvoglar (insulin glargine-aglr), another biosimilar, also appears on many BCBSM formularies at Tier 2. The clinical equivalence is well-established. The INSTRIDE trials demonstrated that biosimilar insulin glargine products produce comparable A1C reductions and hypoglycemia rates to reference Lantus [3].

For a BCBSM member on a typical commercial plan, the practical difference looks like this: Lantus on Tier 3 might carry a $75 copay per 30-day supply, while Semglee on Tier 2 might cost $35. Over 12 months, that difference adds up to $480.

If your physician believes you need brand Lantus specifically (for device familiarity, dosing precision with the SoloStar pen, or documented adverse response to a biosimilar), BCBSM allows formulary exception requests. The prescriber submits clinical rationale, and the plan's pharmacy benefit manager reviews within 72 hours (24 hours for urgent requests).

Prior Authorization and Step Therapy Requirements

BCBSM does not universally require prior authorization for Lantus, but step therapy protocols may apply depending on your diagnosis and plan type.

For Type 1 diabetes members, basal insulin is medically necessary from diagnosis. BCBSM typically approves Lantus or its biosimilars without step therapy for these patients. A confirmed Type 1 diagnosis code (E10.x) on the prescription claim is usually sufficient.

For Type 2 diabetes members on certain plans, BCBSM may enforce step therapy. This means the plan requires documented trial and failure (or contraindication) of preferred agents before approving non-preferred alternatives. In practice, if Semglee is preferred and Lantus is non-preferred, your prescriber may need to document why the biosimilar is inappropriate.

The 2024 American Diabetes Association Standards of Care recommend basal insulin when A1C remains above target despite maximally tolerated metformin and other oral or injectable agents [1]. BCBSM step therapy protocols generally align with ADA sequencing, requiring documentation of prior metformin use (unless contraindicated) before approving any injectable insulin for Type 2 diabetes.

Step therapy override requests require the prescriber to submit a coverage determination form. Common approved reasons include: documented hypoglycemia on a preferred product, allergy to an inactive ingredient in the biosimilar formulation, or inability to use the biosimilar delivery device due to physical limitations.

The $35 Insulin Cap: Medicare and Commercial Implications

The Inflation Reduction Act of 2022 capped insulin cost-sharing at $35 per month for Medicare Part D beneficiaries, effective January 2023 [4]. This applies to all covered insulin products, including Lantus, regardless of tier placement.

For BCBSM Medicare Advantage members enrolled in plans with Part D prescription coverage, Lantus costs no more than $35 for a 30-day supply. The cap applies in the deductible phase, initial coverage phase, and coverage gap (formerly the "donut hole"). This federal protection supersedes whatever tier copay would otherwise apply.

Commercial BCBSM plans are not federally mandated to cap insulin at $35, but Michigan state law and voluntary insurer commitments have expanded protections. Michigan House Bill 4346, signed in 2023, caps insulin copays at $50 per 30-day supply for state-regulated commercial plans [5]. Many BCBSM commercial products voluntarily adopted a $35 cap matching the federal Medicare standard.

Check your plan's prescription drug schedule of benefits to confirm whether the cap applies. Self-funded employer plans (ERISA plans administered by BCBSM) are exempt from state mandates, though many large Michigan employers have voluntarily adopted insulin cost caps.

Quantity Limits and Supply Authorization

BCBSM applies quantity limits to Lantus based on standard dosing protocols from the product's FDA-approved labeling. The typical allowed quantity is one 10 mL vial (1,000 units) or one box of five 3 mL SoloStar pens (1,500 units) per 30 days [6].

Patients requiring higher daily doses may need a quantity limit exception. A patient injecting 80 units of Lantus daily would use 2,400 units per month, exceeding the standard one-vial limit. The prescriber must submit documentation of the prescribed dose, and BCBSM will authorize additional quantity.

The process is straightforward. The pharmacy submits a prior authorization for quantity override. The prescriber confirms the daily dose in writing. Approval typically takes 24-48 hours for standard requests. For patients already established on high-dose basal insulin, annual re-authorization may be required at plan renewal.

90-day supply options are available through BCBSM mail-order pharmacy (Optum Rx for many BCBSM commercial plans) or participating retail pharmacies with 90-day dispensing agreements. Mail-order often reduces per-unit cost and eliminates monthly pharmacy visits.

How to Check Your Specific BCBSM Lantus Coverage

Your coverage depends on multiple variables: plan type (PPO vs. HMO vs. Medicare Advantage), employer group contract terms, formulary year, and whether you've met your deductible. Here is the most reliable verification sequence.

First, locate your plan's formulary. The BCBSM website (bcbsm.com) hosts searchable drug lists organized by plan type. Enter "insulin glargine" or "Lantus" to see tier placement and any restrictions. Second, call BCBSM Pharmacy Services at the number printed on your member ID card. Request a benefits verification for Lantus, specifying the NDC (National Drug Code) your pharmacy will bill: NDC 0024-5323-10 for the 10 mL vial or NDC 0024-5323-05 for the 5-pen box.

Third, ask your pharmacy to run a test claim. This produces a real-time adjudication showing your exact copay, any prior authorization flags, and whether the claim would process. Test claims do not count toward your benefit but reveal exactly what you'd pay today.

If Lantus is denied or placed at a cost you cannot afford, three options exist: switch to a preferred biosimilar (clinically equivalent), request a formulary exception through your prescriber, or appeal the coverage decision through BCBSM's formal grievance process. Michigan insurance regulations require BCBSM to process standard appeals within 30 days and expedited appeals within 72 hours [7].

Lantus Clinical Profile: Why Prescribers Choose It

Insulin glargine (Lantus) provides approximately 24 hours of peakless basal insulin coverage after subcutaneous injection. The ORIGIN trial (N=12,537) demonstrated that early insulin glargine use in people with dysglycemia or early Type 2 diabetes produced neutral cardiovascular outcomes over a median 6.2-year follow-up [8]. This safety data contributed to insulin glargine's position as the most-prescribed basal insulin worldwide for over two decades.

The Treat-to-Target trial established that insulin glargine titrated to fasting glucose targets produces A1C reductions of approximately 1.6 percentage points with lower rates of nocturnal hypoglycemia compared to NPH insulin [9]. This peakless profile is why endocrinologists and primary care physicians continue prescribing glargine-based insulins as first-line basal therapy.

"Basal insulin analogs such as glargine and detemir are preferred over NPH insulin for most patients because of their more predictable pharmacokinetic profiles and reduced hypoglycemia risk," states the ADA's 2024 Standards of Care, Section 9 [1].

For BCBSM members specifically, the clinical equivalence between Lantus and its biosimilars means that switching to a preferred-tier biosimilar does not compromise glycemic control. The FDA's interchangeability designation for Semglee means the products can be substituted at the pharmacy level, similar to generic medications.

Saving Money on Lantus Through BCBSM

Even with insurance coverage, out-of-pocket costs for Lantus can strain household budgets. Several strategies reduce costs specifically for BCBSM members in Michigan.

Manufacturer copay cards from Sanofi (Lantus maker) can reduce commercial plan copays to as low as $0-$25 per prescription for eligible patients. These cards do not work with Medicare, Medicaid, or other government-funded insurance but can layer on top of BCBSM commercial coverage [10].

The Sanofi Patient Connection program provides free Lantus to uninsured or underinsured patients meeting income criteria (generally at or below 400% of the federal poverty level). BCBSM members who face high deductibles early in the plan year may qualify during their deductible phase if their effective out-of-pocket exceeds program thresholds.

Switching to biosimilar insulin glargine remains the most reliable cost reduction for most BCBSM members. The clinical outcomes are equivalent, the delivery devices are similar, and the tier placement typically saves $30-$50 per fill. Discuss with your prescriber whether a switch is appropriate for your situation.

For BCBSM Medicare Advantage members, the $35 cap eliminates the need for manufacturer assistance programs. However, if you're in a commercial plan without a state-mandated cap, combining a manufacturer card with your insurance benefit can reduce costs below what either source would achieve alone.

What Happens If BCBSM Denies Lantus Coverage

A denial doesn't end the conversation. BCBSM members have structured appeal rights under both Michigan insurance law and federal regulations (for Medicare Advantage and ACA marketplace plans).

The most common denial reasons for Lantus are: step therapy not completed (preferred biosimilar not tried first), quantity exceeds plan limits without override authorization, or diagnosis code does not support insulin use (a coding error).

For step therapy denials, the prescriber can submit a coverage exception citing medical necessity. Valid reasons include: documented adverse reaction to the preferred agent, clinical instability that makes switching dangerous, or inability to use the alternative delivery device. The ADA position statement on insulin access notes that "non-medical switching of stable insulin regimens may lead to glycemic disruption and should be avoided when possible" [11].

For quantity limit denials, the fix is straightforward: the prescriber documents the actual prescribed dose, and BCBSM adjusts the allowed quantity. For coding errors, correcting the ICD-10 diagnosis code on the pharmacy claim resolves the issue without formal appeal.

Formal appeals go to BCBSM's internal review committee. If denied internally, Michigan members can request external review through the Michigan Department of Insurance and Financial Services (DIFS). External review decisions are binding on BCBSM.